August 19, 2018 – By Jimmy Cauthen
Nantahala Capital Management Llc decreased its stake in Chemocentryx Inc (CCXI) by 36.46% based on its latest 2018Q1 regulatory filing with the SEC. Nantahala Capital Management Llc sold 344,586 shares as the company’s stock rose 32.26% while stock markets declined. The hedge fund held 600,488 shares of the health care company at the end of 2018Q1, valued at $8.17 million, down from 945,074 at the end of the previous reported quarter. Nantahala Capital Management Llc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $555.68M market cap company. The stock increased 0.73% or $0.08 during the last trading session, reaching $11.03. About 163,923 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since August 19, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9
Westpac Banking Corp decreased its stake in Td Ameritrade Hldg Corp (AMTD) by 19.15% based on its latest 2018Q1 regulatory filing with the SEC. Westpac Banking Corp sold 45,140 shares as the company’s stock rose 5.82% while stock markets declined. The institutional investor held 190,555 shares of the investment bankers and brokers and service company at the end of 2018Q1, valued at $11.29B, down from 235,695 at the end of the previous reported quarter. Westpac Banking Corp who had been investing in Td Ameritrade Hldg Corp for a number of months, seems to be less bullish one the $33.72B market cap company. The stock increased 0.44% or $0.26 during the last trading session, reaching $59.41. About 1.54 million shares traded. TD Ameritrade Holding Corporation (NYSE:AMTD) has risen 57.90% since August 19, 2017 and is uptrending. It has outperformed by 45.33% the S&P500. Some Historical AMTD News: 09/04/2018 – Gabelli & Company’s 12th Annual Omaha Research Trip; 29/03/2018 – MFS Research Fund Adds TD Ameritrade, Exits Halliburton; 03/04/2018 – TD Ameritrade Institutional Welcomes Applications for 2018 NextGen Financial Planning Scholarships & Grants; 26/03/2018 – Broker TD Ameritrade suffers system-wide outage; 21/05/2018 – TD AMERITRADE UNIT ENTERED $850M SR REVOLVING LOAN FACILITY; 07/03/2018 – TD AMERITRADE HOLDING CORP AMTD.O : KBW RAISES TO OUTPERFORM FROM MARKET PERFORM; 14/03/2018 – TD Ameritrade Launches Robust Suite of Charting Tools for Retail Investors; 15/05/2018 – MILLENNIUM EXITED EQIX, AMTD, COO, PUMP, KS IN 1Q: 13F; 30/05/2018 – TD Ameritrade Announces Personalized Portfolios; 05/03/2018 – TD AMERITRADE HOLDING CORP AMTD.O : DEUTSCHE BANK RAISES TARGET PRICE TO $70 FROM $69
Analysts await TD Ameritrade Holding Corporation (NASDAQ:AMTD) to report earnings on October, 23. They expect $0.86 EPS, up 75.51% or $0.37 from last year’s $0.49 per share. AMTD’s profit will be $488.18 million for 17.27 P/E if the $0.86 EPS becomes a reality. After $0.89 actual EPS reported by TD Ameritrade Holding Corporation for the previous quarter, Wall Street now forecasts -3.37% negative EPS growth.
Among 21 analysts covering TD Ameritrade (NYSE:AMTD), 15 have Buy rating, 0 Sell and 6 Hold. Therefore 71% are positive. TD Ameritrade had 101 analyst reports since July 21, 2015 according to SRatingsIntel. Barclays Capital upgraded the stock to “Overweight” rating in Monday, January 8 report. On Friday, May 27 the stock rating was maintained by Deutsche Bank with “Buy”. On Thursday, July 13 the stock rating was maintained by Nomura with “Buy”. The stock of TD Ameritrade Holding Corporation (NASDAQ:AMTD) earned “Sell” rating by Citigroup on Wednesday, July 22. As per Thursday, July 12, the company rating was maintained by Morgan Stanley. Wells Fargo downgraded the stock to “Market Perform” rating in Monday, September 28 report. Wood maintained the stock with “” rating in Wednesday, October 7 report. Deutsche Bank maintained TD Ameritrade Holding Corporation (NASDAQ:AMTD) rating on Tuesday, March 6. Deutsche Bank has “Buy” rating and $70 target. The stock of TD Ameritrade Holding Corporation (NASDAQ:AMTD) earned “Outperform” rating by Wood on Tuesday, March 6. The stock of TD Ameritrade Holding Corporation (NASDAQ:AMTD) has “Hold” rating given on Wednesday, January 10 by Keefe Bruyette & Woods.
Since February 27, 2018, it had 0 insider purchases, and 3 selling transactions for $1.50 million activity. $299,100 worth of TD Ameritrade Holding Corporation (NASDAQ:AMTD) was sold by Quirk Steven M..
Investors sentiment decreased to 1.4 in Q1 2018. Its down 0.28, from 1.68 in 2017Q4. It fall, as 50 investors sold AMTD shares while 71 reduced holdings. 67 funds opened positions while 102 raised stakes. 505.98 million shares or 0.69% more from 502.49 million shares in 2017Q4 were reported. Jump Trading Ltd Limited Liability Company reported 3,832 shares or 0.02% of all its holdings. 11,327 were accumulated by Jefferies Grp Ltd Limited Liability Company. Bokf Na accumulated 3,590 shares. Atlantic Trust Gru Ltd Llc holds 296,740 shares. Ent Fincl Service Corp reported 0% in TD Ameritrade Holding Corporation (NASDAQ:AMTD). Natl Bank Of America Corp De owns 990,405 shares. Pitcairn has 3,663 shares. America First Limited Liability Corp accumulated 2,600 shares. First Personal Fincl reported 2,872 shares or 0.04% of all its holdings. Sg Americas Securities accumulated 7,436 shares or 0% of the stock. Da Davidson, Montana-based fund reported 6,660 shares. 10,460 are owned by Oakbrook Invests Limited Com. State Of Wisconsin Board has 0.04% invested in TD Ameritrade Holding Corporation (NASDAQ:AMTD) for 236,784 shares. Brown Brothers Harriman holds 0% of its portfolio in TD Ameritrade Holding Corporation (NASDAQ:AMTD) for 185 shares. Fdx Incorporated invested in 8,634 shares.
Westpac Banking Corp, which manages about $5007.51B US Long portfolio, upped its stake in Procter And Gamble Co (NYSE:PG) by 27,260 shares to 305,917 shares, valued at $24.25B in 2018Q1, according to the filing. It also increased its holding in Blue Apron Hldgs Inc by 997,904 shares in the quarter, for a total of 1.57 million shares, and has risen its stake in Synopsys Inc (NASDAQ:SNPS).
Investors sentiment decreased to 1 in 2018 Q1. Its down 0.30, from 1.3 in 2017Q4. It is negative, as 10 investors sold CCXI shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. Citadel Advsr Limited Liability holds 0% or 18,829 shares in its portfolio. Public Employees Retirement Systems Of Ohio has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Clarivest Asset Management holds 79,000 shares or 0.02% of its portfolio. 2.38 million were accumulated by Wasatch. Moreover, Proshare Advisors Ltd Liability Corporation has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 25,705 shares. Acadian Asset Management Limited Liability Company invested in 0.03% or 521,864 shares. California-based Farallon Mgmt Ltd Company has invested 0.09% in ChemoCentryx, Inc. (NASDAQ:CCXI). Pnc Finance Group reported 219,821 shares or 0% of all its holdings. Morgan Stanley reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Bvf Il holds 7.20M shares or 9.93% of its portfolio. Vanguard Group holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 1.22 million shares. Bridgeway Capital Mngmt has 50,246 shares. Jpmorgan Chase & Company accumulated 0% or 67,861 shares. The California-based Franklin Resources has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Schwab Charles Inv Inc accumulated 0% or 43,100 shares.
Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on November, 6. They expect $-0.26 earnings per share, down 100.00% or $0.13 from last year’s $-0.13 per share. After $-0.14 actual earnings per share reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 85.71% negative EPS growth.
Since May 1, 2018, it had 0 buys, and 12 insider sales for $7.89 million activity. Another trade for 200,000 shares valued at $2.36 million was made by Schall Thomas J. on Tuesday, May 15. $1.34M worth of stock was sold by KANAYA SUSAN M on Tuesday, June 26.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Benzinga.com which released: “45 Stocks Moving In Tuesday’s Mid-Day Session” on August 14, 2018, also Nasdaq.com with their article: “ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights” published on August 09, 2018, Nasdaq.com published: “ChemoCentryx to Hold Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018” on August 02, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “ChemoCentryx 2018 Q2 – Results – Earnings Call Slides” published on August 10, 2018 as well as Benzinga.com‘s news article titled: “58 Biggest Movers From Yesterday” with publication date: August 15, 2018.
Among 7 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. ChemoCentryx had 10 analyst reports since September 3, 2015 according to SRatingsIntel. The stock has “Neutral” rating by JP Morgan on Tuesday, August 14. The rating was maintained by JP Morgan on Tuesday, March 13 with “Overweight”. JMP Securities initiated ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, February 21 with “Mkt Outperform” rating. Zacks downgraded ChemoCentryx, Inc. (NASDAQ:CCXI) on Thursday, September 3 to “Sell” rating. The stock has “Buy” rating by JMP Securities on Thursday, August 10. Cowen & Co maintained the stock with “Hold” rating in Tuesday, August 8 report. The firm earned “Sell” rating on Monday, September 21 by Zacks.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.